Abstract 1520P
Background
The NAPOLI 3 trial reported a survival benefit with the combination therapy nanoliposomal Irinotecan, 5-Fluorouracil, Leucovorin and Oxaliplatin (NALIRIFOX) versus nabPaclitaxel and Gemcitabine in first line therapy for metastatic pancreatic ductal Adenocarcinoma (mPDAC). In this study we aim to analyze the efficacy and feasibility of this promising new first line regime in an early real-world setting.
Methods
The analyzed population included patients with unresectable or metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX at 3 Austrian cancer centers. The primary endpoint of the study was overall survival (OS), while secondary endpoints included progression free survival (PFS), overall response rate (ORR), and safety. All patient data including molecular profiles were obtained by individual chart review.
Results
From February 2023 to April 2024, 40 patients were enrolled. After a median follow up of 7.9 months (95% CI 6.44-10.36), median PFS was 5.3 months (95% CI 3.45-6.71), and median OS was 12.7 months (95% CI 8.94-NR). The investigator assessed confirmed ORR was 63% and the disease control rate was 78%. Any grade adverse events (AEs) occurred in 40 patients (100%). Grade 3-4 AEs occurred in 17 patients (42.50%). The most common side effects were hypokalemia (53.13%) and diarrhea (52.5%). Among hypokalemia cases, 82% experienced severe (G3/G4) adverse events, while for diarrhea, the percentage of severe AEs was 19%. In 9 patients (22.50%) treatment-emergent adverse events leading to discontinuation. No treatment-related treatment-emergent adverse events leading to death were detected. KRAS was present in 87.5%.
Conclusions
To the best of our knowledge this is the first real-world analysis of NALIRIFOX in pancreatic cancer. Efficacy results confirm the phase NAPOLI 3 trial while holding promising safety.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Reichinger.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1465P - Potential impact of APC mutation on survival via immune evasion through WNT signaling activation in HER2-positive gastric cancer treated with trastuzumab (tmab), nivolumab (nivo), and chemotherapy
Presenter: Takeru Wakatsuki
Session: Poster session 18
1468P - cGAS-driven inflammation in chromosomally unstable oesophagogastric adenocarcinoma
Presenter: Eileen Parkes
Session: Poster session 18
1469P - Development of an efficacy prediction model for concurrent chemoradiotherapy in esophageal squamous cell carcinoma using deep learning and multimodal data integration
Presenter: Xin Yang
Session: Poster session 18
1470TiP - Phase I trial of intraperitoneal infusion of GAIA-102 of NK-Like CD3-negative cells for gastric/pancreatic cancer
Presenter: Eiji Oki
Session: Poster session 18
1471TiP - MK-2870-015: A phase III study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) vs treatment of physician’s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)
Presenter: Zev Wainberg
Session: Poster session 18
1472TiP - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group – The IKF-057/ PRESTO trial
Presenter: Nils Homann
Session: Poster session 18
1473TiP - Neoadjuvant SOX combined with cadonilimab (AK104) for PD-L1 negative upper GC/GEJC patients
Presenter: Zhen Yuan
Session: Poster session 18
1474TiP - A randomized phase II study of disitamab vedotin (DV) plus toripalimab and chemotherapy versus DV plus toripalimab versus chemotherapy as perioperative treatment for HER2-expressing locally advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ)
Presenter: Ziyu Li
Session: Poster session 18